Nanotechnology and glaucoma: little particles for a big dise... : Current Opinion in Ophthalmology
Nanotechnology and glaucoma: little particles for a big disease : Current Opinion in …

Glaucoma, a disease of the optic nerve and retina, causes blindness in millions of people
worldwide. Currently available therapies for this disease only attempt to reduce intraocular …

Glaucoma, a chronic progressive neuropathy and the most frequent cause of irreversible
blindness worldwide, is commonly treated by medication or surgery aimed at lowering …

Methods.: A Markov decision-analytic health model was developed to determine the cost-
effectiveness of treating NTG with IOP lowering therapy to prevent progressive visual field …

Given that glaucoma is a disease of the central nervous system, there must be greater
emphasis and focus on developing intraocular pressure–independent therapies. In addition …

Neben der klassischen Augeninnendrucksenkung kommen zunehmend auch ergänzende
Therapiestrategien für die Behandlung eines Glaukoms infrage. Aus diesem Grund …

Purpose: To describe a new familial syndrome consisting of anterior segment dysgenesis,
glaucomatous optic neuropathy, and intraocular pressure (IOP) in the normal range. Design …

Current pharmacological therapies for the treatment of chronic optic neuropathies such as
glaucoma are often inadequate due to their inability to directly affect the optic nerve and …

Melatonin is currently considered as a promising drug for glaucoma treatment due to its
ocular hypotensive and neuroprotective effects. We have investigated the effect of melatonin …

Для сохранения зрительных функций у больных глаукомой используется
гипотензивная терапия. В статье обсуждаются вопросы выбора целевого уровня …